---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027975"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:03:55.807077+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BMS terminates collaboration on CC-99712; Sutro regains full rights

## Summary
- BMS notified Sutro on June 9, 2023 of termination of Amended Collaboration and License Agreement for CC-99712.
- Termination effective October 7, 2023; decision attributed to BMS portfolio prioritization.
- After termination, Sutro regains sole worldwide rights to the BCMA-targeting antibody-drug conjugate program.
- No financial terms, termination payments, or immediate impact on cash runway disclosed.

## SEC filing metadata
- accession: 0000950170-23-027975
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/stro-20230608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027975
- JSON: https://secwatch.observer/filing/0000950170-23-027975.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027975.txt

## Key facts
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers at the 2023-06-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: 3. Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 39,146,793 9,377,370 17,368 4,402,194
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2023-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: On June 8, 2023, the Company held its 2023 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of three Class II directors, identified in the table below, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Broker Non-Votes William J. Newell 39,690,178 8,851,353 4,402,194 Connie Matsui 29,080,240 19,461,291 4,402,194 James Panek 31,714,990 16,826,541 4,402,194
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: 2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Abstaining Broker Non-Votes 52,888,041 42,108 13,576 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm
- Shareholder Votes
  SUTRO BIOPHARMA, INC. shareholders approved Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions at the 2023-06-08 meeting.
  - Proposal: charter amendment
  - Outcome: passed
  - Meeting: 2023-06-08
  source text: 4. Approval of the amendment and restatement of the Company’s amended and restated certificate of incorporation to permit the exculpation of the Company’s officers from personal liability for certain breaches of the duty of care in certain actions: Shares For Shares Against Shares Abstaining Broker Non-Votes 43,016,509 5,507,942 17,080 4,402,194
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023027975/0000950170-23-027975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.